Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 7/20 | 0.55 |
| ▸ | KDR | P35968 | 7/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334220 | 0.91 | AURKA (0.46) | AURKAKDRNR1H2BRD4CREBBP | |
| SCHEMBL5333314 | 0.87 | KDR (0.52) | AURKAKDRNR1H2BRD4CREBBP | |
| SCHEMBL5331995 | 0.86 | AURKA (0.42) | AURKAKDRNR1H2BRD4CREBBP | |
| SCHEMBL5327530 | 0.85 | AURKA (0.48) | AURKAKDRNR1H2BRD4CREBBP | |
| SCHEMBL5315294 | 0.84 | AURKA (0.59) | AURKAKDRNR1H2 | |
| SCHEMBL5330620 | 0.84 | BRD4 (0.55) | NR1H2BRD4CREBBPNR1H3 | |
| SCHEMBL5332483 | 0.84 | NR1H2 (0.38) | AURKAKDRNR1H2BRD4CREBBP | |
| SCHEMBL5335112 | 0.83 | AURKA (0.60) | AURKAKDRNR1H2BRD4CREBBP | |
| SCHEMBL5329167 | 0.81 | AURKA (0.39) | AURKAKDRNR1H2BRD4CREBBP | |
| SCHEMBL3043809 | 0.80 | NR1H2 (0.41) | AURKAKDRNR1H2BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | claimed |
| WO-2007047646-A2 | SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | WO | claimed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| WO-2007047646-A2 | SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047646-A2 | SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | MAP3K20, MAP3K3, MAP3K19 | AURKA 669/4885KDR 1627/4885NR1H2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.